Jan Wald
Jan Wald
acid might passed test
They might have passed the acid test of being too big.
earnings interest investor renew report
There was nothing in the earnings report that would renew investor interest.
among employees
There's a lot of frustration among institutional shareholders and employees who own the stock.
less serious
It's less serious than I thought it was.
closing concerned delay interest though
Integration is going full-speed ahead. I don't think they would be concerned by a two-week delay in closing the deal, even though there's an interest payment.
boston heard scientific single
I haven't heard from a single Guidant shareholder who doesn't like the Boston Scientific deal.
hurting
I think of all the pieces, it's pharmaceuticals that are hurting them the most.
relationship speech
If the relationship has been adversarial, the FDA, we believe, would not be as accommodating, even in speech.
ask boston hold holding johnson paper rather whether
If you're a Guidant shareholder, you have to ask yourself whether you'd rather hold Boston paper or Johnson & Johnson paper. I would rather hold Boston, because I'm holding Guidant for growth.
buying company easy faces growth half impact johnson problem size
The problem that Johnson & Johnson and any company even half the size of Johnson & Johnson faces is buying something that can impact their growth rate, and that's not an easy task.
hard people work
People are Guidant's most important asset, ... so there are hard trade-offs for Guidant to work through.
boston buying good insider investors scientific
I think investors do take insider buying as a good sign, and I think they especially wanted Boston Scientific to do it.
appears doctors faster fresh good perhaps portion willing
It appears that a good portion of doctors are willing to give Guidant a fresh look in their practices, and perhaps faster than most believed.
amazing events turn
I think it's an amazing turn of events.